הטיפול בסרטן מנקודת מבט של משפחת חולה

מספיקים הכירורגים. יש לחזור לטיפולים הטבעיים הקיימים משנת 2000 לפני הספירה.

Breast Cancer Res Treat. 2008 Oct 7. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Greenlee H, Hershman DL, Jacobson JS. Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th St., 7th Floor, New York, NY, 10032, USA, Purpose: An estimated 45-80% of breast cancer patients use antioxidant supplements after diagnosis, AND use of antioxidant supplements during breast cancer treatment is common. Dietary supplements with antioxidant effects include vitamins, minerals, phytonutrients, AND other natural products. We conducted a comprehensive review of literature on the associations between antioxidant supplement use during breast cancer treatment AND patient outcomes. Methods Inclusion criteria were: two OR more subjects; clinical trial OR observational study design; use of antioxidant supplements (vitamin C, vitamin E, antioxidant combinations, multivitamins, glutamine, glutathione, melatonin, OR soy isoflavones) during chemotherapy, radiation therapy, and/or hormonal therapy for breast cancer as exposures; treatment toxicities, tumor response, recurrence, OR survival as outcomes. Results: We identified 22 articles that met those criteria. Their findings did not support any conclusions regarding the effects of individual antioxidant supplements during conventional breast cancer treatment on toxicities, tumor response, recurrence, OR survival. A few studies suggested that antioxidant supplements might decrease side effects associated with treatment, including vitamin E for hot flashes due to hormonal therapy AND glutamine for oral mucositis during chemotherapy. Underpowered trials suggest that melatonin may enhance tumor response during treatment. Conclusion: The evidence is currently insufficient to inform clinician AND patient guidelines on the use of antioxidant supplements during breast cancer treatment. Thus, well designed clinical trials AND observational studies are needed to determine the short- AND long-term effects of such agents.

J Natl Cancer Inst. 2007 May 16;99(10):754-64 Multivitamin use AND risk of prostate cancer in the National Institutes of Health-AARP Diet AND Health Study. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, Leitzmann MF. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA. [email protected] BACKGROUND: Multivitamin supplements are used by millions of Americans because of their potential health benefits, but the relationship between multivitamin use AND prostate cancer is unclear. METHODS: We prospectively investigated the association between multivitamin use AND risk of prostate cancer (localized, advanced, AND fatal) in 295,344 men enrolled in the National Institutes of Health (NIH)-AARP Diet AND Health Study who were cancer free at enrollment in 1995 AND 1996. During 5 years of follow-up, 10,241 participants were diagnosed with incident prostate cancer, including 8765 localized AND 1476 advanced cancers. In a separate mortality analysis with 6 years of follow-up, 179 cases of fatal prostate cancer were ascertained. Multivitamin use was assessed at baseline as part of a self-administered, mailed food-frequency questionnaire. Relative risks (RRs) AND 95% confidence intervals (CIs) were calculated by use of Cox proportional hazards regression, adjusted for established OR suspected prostate cancer risk factors. RESULTS: No association was observed between multivitamin use AND risk of localized prostate cancer. However, we found an increased risk of advanced AND fatal prostate cancers (RR = 1.32, 95% CI = 1.04 to 1.67 AND RR = 1.98, 95% CI = 1.07 to 3.66, respectively) among men reporting excessive use of multivitamins (more than seven times per week) when compared with never users. The incidence rates per 100,000 person-years for advanced AND fatal prostate cancers for those who took a multivitamin more than seven times per week were 143.8 AND 18.9, respectively, compared with 113.4 AND 11.4 in never users. The positive associations with excessive multivitamin use were strongest in men with a family history of prostate cancer OR who took individual micronutrient supplements, including selenium, beta-carotene, OR zinc. CONCLUSION: These results suggest that regular multivitamin use is not associated with the risk of early OR localized prostate cancer. The possibility that men taking high levels of multivitamins along with other supplements have increased risk of advanced AND fatal prostate cancers is of concern AND merits further evaluation.